PDL BioPharma (PDLI) Tops Q2 EPS by 1c

PDL BioPharma (NASDAQ: PDLI) reported Q2 EPS of $0.09, $0.01 better than the analyst estimate of $0.08. Revenue for the quarter came in at $21 million versus the consensus estimate of $33.46 million.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c